Continue Enoxaparin at Full Dose
With a platelet count of 120 × 10⁹/L, enoxaparin should be continued at the same therapeutic dose without modification. This platelet level is well above the threshold requiring dose adjustment.
Guideline-Based Recommendations
The most recent international guidelines 1 explicitly state that full doses of anticoagulant can be used for treatment of established VTE if the platelet count is >50 × 10⁹/L and there is no evidence of bleeding. Your patient's platelet count of 120 × 10⁹/L is more than double this threshold.
The 2018 ISTH consensus 2 reinforces this approach with clear guidance:
- Full therapeutic anticoagulation without platelet transfusion is recommended for patients with cancer-associated thrombosis and platelet count ≥50 × 10⁹/L
- Dose modifications only become necessary when platelets drop below 50 × 10⁹/L
Specific Platelet-Based Dosing Algorithm
For future reference, here is the evidence-based approach to enoxaparin dosing based on platelet counts 2:
Platelet ≥50 × 10⁹/L:
- Continue full therapeutic dose
- No transfusion support needed
- No dose modification required
Platelet 25-50 × 10⁹/L:
- Reduce to 50% of therapeutic dose OR use prophylactic dosing
- Consider risk stratification (acute vs. chronic VTE, high vs. low risk features)
Platelet <25 × 10⁹/L:
- Temporarily discontinue anticoagulation
- Resume when platelet count rises above thresholds
Supporting Evidence
Validation studies support the safety of this approach. A quality assessment study at Memorial Sloan Kettering 3 demonstrated that following these platelet-based dose modification guidelines resulted in no recurrent VTE events and no major bleeding episodes when anticoagulation was appropriately dosed or held based on platelet thresholds.
Similarly, research in hematopoietic stem cell transplant patients 4 found that reduced-dose enoxaparin during thrombocytopenia was effective with no major bleeding events, though this was specifically for platelets <50 × 10⁹/L.
Key Clinical Caveats
- Active bleeding is an absolute contraindication regardless of platelet count
- Monitor for bleeding symptoms at any platelet level
- The 50 × 10⁹/L threshold applies specifically to cancer-associated thrombosis; some guidelines suggest 80 × 10⁹/L for prophylactic dosing 1
- These recommendations assume LMWH (enoxaparin) use; DOACs lack safety data in severe thrombocytopenia
Bottom line: At 120 × 10⁹/L, continue your current enoxaparin dose unchanged and monitor platelet counts regularly. Only consider dose modification if platelets drop below 50 × 10⁹/L 2, 1.